Stephanie Boehm
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Fibroblast Growth Factor Research, Cancer, Hypoxia, and Metabolism, Pancreatic function and diabetes, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Most-Cited Works
- → Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19(2020)187 cited
- → Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases(2021)55 cited
- → Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis(2022)54 cited
- → Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119(2014)45 cited
- → MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity(2022)39 cited
- → Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model(2024)11 cited
- → LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation(2019)11 cited
- → Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of nonalcoholic steatohepatitis(2018)8 cited
- → Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis(2022)4 cited
- → A PEGylated fibroblast growth factor 21 variant improves hepatic steatosis in a mouse model of non-alcoholic steatohepatitis, as determined by magnetic resonance imaging-derived hepatic fat-fraction(2018)3 cited